Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from July 22, 2025

Partial Published before the outcome was known, scored automatically when the window closed on October 20, 2025 — -15.5% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$63.56 – $66.00Entry zone — fair-value band

$65.97Published — price the day we called it

$79.58Target — the price the thesis aimed for

$71.00Peak — highest point inside the window, not a realized return

$55.74Window close — end-of-window price, context only

What happened

Partial

Reached 35% of the predicted growth at its peak, without hitting the target.

At window close

-15.5%

realized, from the publication price to the last close inside the window

Peak gain

+7.6%

peak, from the publication price — not a realized return

S&P 500, same window

+7%

SPY over the identical days, dividend-adjusted

Window close

$55.74

last close inside the window, ended October 20, 2025

Peak price

$71.00

peak on July 25, 2025 — not a realized return

Days to target

—

The thesis — published July 22, 2025

Predicted growth

+22%

over the measurement window

Target price

$79.58

the price the thesis aimed for

Entry zone

$63.56 – $66.00

the fair-value band we waited for

Price at publication

$65.97

published July 22, 2025

Confidence

85%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Shares have fallen by more than half since early 2024, even though sales of its key drug jumped 50% and a study showed it cuts heart problems by 20%. A yes/no decision from US regulators by Sept 4 could let the drug be marketed for heart health, and a new North Carolina factory will boost output 25% this winter. Profit margins stay above 80% and the company is already buying back $5.5 B of its own stock, so a bounce toward the low $80s in the next three months seems doable.

Primary drivers

FDA may allow Wegovy to claim heart benefits on Sept 4, boosting insurance coverage.
New North Carolina site will raise output by 25% in late 2024, easing product shortages.
Stock is 50% below its high yet profit margins over 80% and strong returns limit downside.
$5.5 B share buyback through Q3 means steady demand for the stock and higher earnings per share.

How it played out

NVO: target was not reached

Lyra published NVO on 2025-07-22 at 65.97, with expected growth of 22% toward 79.58. The thesis pointed to a possible FDA decision on Wegovy heart-benefit claims by Sept. 4, added North Carolina output, profit margins above 80%, and a $5.5 B buyback. It also noted sales of a key drug had jumped 50% and a study showed a 20% cut in heart problems.

Inside the window, NVO rose to 71 on 2025-07-25, a 7.6% peak gain. The stock stayed below 79.58 and never reached the target. It ended at 55.74 on 2025-10-20. The thesis only partly played out.

What happened during the window

On 2025-07-29, Kiplinger reported that Novo Nordisk cut its 2025 outlook and said the change related to lower growth expectations for Wegovy and Ozempic in the U.S. On 2025-09-10, Cinco Días reported that Novo Nordisk announced 9,000 job cuts, about 11% of its workforce.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals